David Melamed, PhD,  —

HRA Pharma Rare Diseases has named AllianceRx Walgreens Prime as its exclusive pharmacy distributor for two rare disease medications: Metopirone (metyrapone), used to diagnose Cushing’s syndrome, and Lysodren (mitotane), an approved treatment for people with adrenocortical carcinoma, a rare cancer of the adrenal…

Isturisa (osilodrostat) oral treatment for Cushing’s disease patients is now fully available to be sold and distributed across the United States, according to its developer Recordati Rare Diseases. The move follows Isturisa’s recent approval by the U.S. Food and Drug Administration (FDA) for adult…

Recordati Rare Diseases announced that it has officially acquired marketing rights in Europe for the Cushing’s treatment Isturisa (osilodrostat), enabling the company to distribute it throughout the European Union, as well as in the U.K., Norway, Liechtenstein, and Iceland. The company — a subsidiary of Recordati, based in Italy…

People with Cushing’s syndrome who undergo surgery to remove one or both adrenal glands experience a persistent decrease in kidney function after one month that does not seem to worsen or improve with time, a study has found. The study, “Postoperative renal impairment and longitudinal change…

Secretion of multiple hormones, high morning cortisol levels, higher tumor grade, and diabetes are all significantly associated with a worse prognosis for people with ectopic Cushing’s syndrome (ECS) caused by a neuroendocrine tumor, a new study found. The study, “Multiple hormone secretion may indicate…